Clinical Trial Update: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A multicenter open-label Phase 1b/2 trial of oprozomib with dexamethasone in relapsed/refractory multiple myeloma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Oprozomib (oprozomib)

Snippet

Sponsor: Amgen | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-07-13